Blockchain Registration Transaction Record

NRx Pharmaceuticals Files Patent for NRX-100 IV Ketamine Formulation for Suicidal Depression

NRx Pharmaceuticals has filed a patent application for NRX-100, a preservative-free intravenous ketamine formulation targeting suicidal depression. The patent could provide exclusivity through 2045, potentially revolutionizing the treatment approach for this critical mental health condition.

This news matters as NRX Pharmaceuticals' patent application for NRX-100 signifies a groundbreaking development in the treatment of suicidal depression. The potential exclusivity through 2045 and the preservative-free nature of NRX-100 could revolutionize the approach to managing this critical mental health condition. The filing aligns with NRx Pharmaceuticals' mission to provide innovative solutions for central nervous system disorders, offering hope to individuals suffering from suicidal bipolar depression.